News Sentiment

MDXH sentiment intelligence

MDxHealth SA ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 0.48 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-0.1% over one week, -12.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

AWM amendment: no MDxHealth holdings reported (MDXH)

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -0.1% Price digesting
Trend fit Trend inactive -12.2% over four weeks
Fair value -82.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 24
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingView 6
TradingKey 6
simplywall.st 4
The Manila Times 2
MT Newswires 2
Investing.com 2
AD HOC NEWS 1

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 11
Analyst action 3
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
Stock Titan Direct company coverage

AWM amendment: no MDxHealth holdings reported (MDXH)

AWM Investment Company, Inc. has filed an amendment to a Schedule 13G/A, reporting that it holds no beneficial ownership in MDxHealth (MDXH). The filing indicates that AWM and its associated funds own 0 shares, representing 0% of the class of Common Stock, No Par Value (CUSIP B59

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of MDxHealth SA – NASDAQ:MDXH

This article provides financial information for MDxHealth SA (NASDAQ: MDXH), focusing on its enterprise value to revenue forward metric. The content highlights the availability of financial data through TradingView, noting market status and data sources. It appears to be a stub o

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 19:43
Source
TradingView
AD HOC NEWS Direct company coverage

MDxHealth SA explores US growth opportunities as diagnostics demand evolves

MDxHealth SA, a molecular diagnostics company specializing in urology and prostate cancer testing, is focused on expanding its presence in the US market. The company seeks to increase the adoption of its diagnostic assays among physicians and health systems to support precision m

Tone
Neutral 50/100
Event
Macro sensitivity
Published
07 Jul 2026 14:40
Source
AD HOC NEWS
TradingView Direct company coverage

Price to book forward of MDxHealth SA – NASDAQ:MDXH

This article provides financial data for MDxHealth SA (NASDAQ: MDXH), specifically its price-to-book forward ratio. The content is presented within the context of TradingView's market analysis platform, indicating that the information is part of a larger financial overview for th

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 04:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of MDxHealth SA – NASDAQ:MDXH

The article focuses on the "Price to sales forward" metric for MDxHealth SA, traded on NASDAQ under the symbol MDXH. It appears to be a financial data snippet from TradingView, highlighting this specific financial ratio for the company. The content primarily lists navigation and

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 02:10
Source
TradingView
The Manila Times Direct company coverage

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Mdxhealth SA announced it received a notification from Nasdaq due to non-compliance with the minimum bid price requirement of US$1.00 per share. The company has 180 calendar days, until December 28, 2026, to regain compliance by having its shares close at or above US$1.00 for at

Tone
Negative 40/100
Event
Market update
Published
03 Jul 2026 16:40
Source
The Manila Times
MSN Direct company coverage

Mdxhealth receives NASDAQ non-compliance notice after $1 bid price breach

Mdxhealth (MDXH) has received a notice from NASDAQ for non-compliance with its minimum bid price requirement, as its stock traded below $1 for 30 consecutive business days. The company has 180 calendar days, until June 30, 2024, to regain compliance by ensuring its stock trades a

Tone
Negative 28/100
Event
Market update
Published
02 Jul 2026 22:39
Source
MSN
Stock Titan Direct company coverage

Nasdaq warns mdxhealth (NASDAQ: MDXH) on $1 bid rule, eyes reverse split

Mdxhealth (NASDAQ: MDXH) has received a notice from Nasdaq for non-compliance with the minimum $1.00 bid price requirement, as its shares traded below this threshold for 30 consecutive days. The company has 180 calendar days, until December 28, 2026, to regain compliance by maint

Tone
Negative 18/100
Event
Market update
Published
02 Jul 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Mdxhealth gets 180 days to fix Nasdaq bid-price issue

Mdxhealth (NASDAQ: MDXH) received a Nasdaq notification on New Year's Eve 2026, indicating its shares no longer meet the US$1.00 minimum bid price requirement for continued listing. The company has 180 days, until December 28, 2026, to regain compliance, and may consider options

Tone
Negative 28/100
Event
Market update
Published
02 Jul 2026 19:39
Source
Stock Titan
The Manila Times Direct company coverage

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial

Mdxhealth announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, a significant milestone for their collaboration with the University of Oxford. This study provides the scientific foundation for the ongoing GPS-ProtecT randomized clini

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 14:39
Source
The Manila Times
TradingView Direct company coverage

MDxHealth S.A. Actuals & Estimates (NASDAQ:MDXH)

The article provides an overview of MDxHealth SA's financial data, analyst estimates, and stock performance on NASDAQ. It covers current stock price, historical highs and lows, volatility, market capitalization, earnings reports, revenue, net income, and future forecasts. The com

Tone
Negative 29/100
Event
Earnings
Published
26 Jun 2026 12:40
Source
TradingView
TradingView Direct company coverage

MDxHealth S.A. Actuals & Estimates (SWB:O6C1)

This article provides an overview of MDxHealth S.A. (SWB:O6C1) financial actuals and estimates, including its stock ticker, forecast, historical prices, and upcoming earnings reports. It details recent earnings, revenue, net income, EBITDA, and employee count, clarifying that the

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

MDXH Forecast — Price Target — Prediction for 2027

This article provides a forecast for MDxHealth SA (MDXH) stock, including analyst price targets, current stock performance, and financial metrics. Analysts have given a max estimate of $5.00 and a min estimate of $1.00 for MDXH's future price, despite recent significant declines

Tone
Negative 29/100
Event
Analyst action
Published
26 Jun 2026 00:11
Source
TradingView
TradingKey Direct company coverage

MDxHealth SA (MDXH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MDxHealth SA (MDXH), focusing on its support and resistance levels, key indicators, and moving averages. The stock is currently trading between a resistance of 0.67 and support of 0.30, suggesting suitability for range-bound swing tra

Tone
Negative 28/100
Event
Market update
Published
24 Jun 2026 12:40
Source
TradingKey
Intellectia AI Direct company coverage

MDXH PE Ratio & Valuation, Is MDXH Overvalued

MDxHealth SA (MDXH) is currently undervalued, with a forward PS ratio of 0.26 compared to its five-year average of 2.39. Its fair price is estimated to be between $1.47 and $3.82, suggesting it is undervalued by 65.01% relative to its current price of $0.51. The article also prov

Tone
Positive 72/100
Event
Market update
Published
23 Jun 2026 11:40
Source
Intellectia AI
TradingKey Direct company coverage

MDxHealth SA (MDXH) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for MDxHealth SA (MDXH), highlighting a current earnings forecast score of 7.67, ranking it 278 out of 389 in its industry. Analysts set an average price target of $7.00, with a consensus "Buy" rating based on 6 analysts. The report also

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

MDxHealth SA (MDXH) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of MDxHealth SA (MDXH), noting its stable financial status and high operating efficiency. The company's current financial score is 7.20, ranking 141 out of 388 in its industry. MDxHealth SA reported a 12.74% year-over-year increase in qu

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 09:10
Source
TradingKey
TradingKey Direct company coverage

MDxHealth SA (MDXH) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for MDxHealth SA (MDXH), noting its current risk assessment score of 2.78, ranking it 189 out of 388 in the Biotechnology & Medical Research industry. The company's beta of 0.56 indicates it tends to underperform during upward markets but e

Tone
Negative 37/100
Event
Analyst action
Published
18 Jun 2026 09:10
Source
TradingKey
TradingKey Direct company coverage

MDxHealth SA (MDXH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of MDxHealth SA (MDXH), listing its major individual and institutional holders and their respective proportions. It also presents a breakdown of shareholder types and institutional shareholding data over several quarters, highlightin

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 06:10
Source
TradingKey
TradingKey Direct company coverage

MDxHealth SA (MDXH) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of MDxHealth SA (MDXH) from TradingKey, noting a current valuation score of 9.03, ranking it 65th out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -0.86, showing a slight decrease from i

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 05:10
Source
TradingKey
Stock Titan Direct company coverage

Director Don M. Hardison granted 10,000 MDxHealth (MDXH) options at $0.76

MDxHealth's director, Don M. Hardison, was granted 10,000 share options at an exercise price of $0.76 per share, effective June 1, 2026. These compensation-related options vest in full at the annual general shareholders' meeting in the calendar year following the grant and expire

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 16:09
Source
Stock Titan
Stock Titan Direct company coverage

MDxHealth (NASDAQ: MDXH) CEO granted 942,200 share options at $0.76 strike

MDxHealth SA CEO Michael McGarrity was granted two share option awards totaling 942,200 options, each exercisable at $0.76 per share and expiring on May 28, 2036. One grant of 612,400 options vests based on Company performance criteria, while the other grant of 329,800 options ve

Tone
Positive 61/100
Event
Market update
Published
04 Jun 2026 03:39
Source
Stock Titan
Stock Titan Direct company coverage

MDxHealth (MDXH) director Koen Hoffman awarded 10,000 share options via Ahok BV

MDxHealth director Koen Hoffman was granted 10,000 share options through his indirect holding company, Ahok BV, as reported in a Form 4 filing. These options, exercisable at $0.76 per share and expiring on May 28, 2036, are a compensation-related award and will vest fully on the

Tone
Positive 59/100
Event
Market update
Published
04 Jun 2026 03:39
Source
Stock Titan
Stock Titan Direct company coverage

MDxHealth (MDXH) director Michael Holder receives 10,000 share option grant

Michael Holder, a director at MDxHealth SA (MDXH), has been granted options to purchase 10,000 ordinary shares as part of an equity incentive award. The options have an exercise price of $0.76 per share and will vest in full on the date of the annual general shareholders' meeting

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

MDxHealth (NASDAQ: MDXH) grants Joseph Sollee 237,100 share options

MDxHealth SA officer Joseph Sollee has been granted 237,100 share options, split into two grants, as equity compensation. Both grants have an exercise price of $0.76 per share and expire in 2036. One grant of 154,100 options vests based on company performance criteria, while the

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

MDxHealth (MDXH) awards new share options to finance VP

MDxHealth SA's VP of Finance and Accounting, Brendan O'Connell, was granted two sets of share options: 65,000 performance-based options and 35,000 time-based options, both at an exercise price of $0.76 per share. This increases his derivative-based compensation. The performance-b

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

MDxHealth (MDXH) director granted options on 10,000 shares

MDxHealth director Sanford Jay Siegel was granted options on 10,000 ordinary shares with an exercise price of $0.76 per share. These options are part of his compensation, vest in full at the annual general shareholders' meeting in the year after the grant, and expire on May 28, 2

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 21:09
Source
Stock Titan